UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
,
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events |
On February 26, 2025, Johnson & Johnson (the “Company”) completed the previously announced public offerings of the following:
| (1) | €600,000,000 aggregate principal amount of 2.700% Notes due 2029 (the “2029 Notes”); |
| (2) | €700,000,000 aggregate principal amount of 3.050% Notes due 2033 (the “2033 Notes”); |
| (3) | €1,000,000,000 aggregate principal amount of 3.350% Notes due 2037 (the “2037 Notes”); |
| (4) | €700,000,000 aggregate principal amount of 3.600% Notes due 2045 (the “2045 Notes”); and |
| (5) | €1,000,000,000 aggregate principal amount of 3.700% Notes due 2055 (the “2055 Notes” and, together with the 2029 Notes, the 2033 Notes, the 2037 Notes and the 2045 Notes, the “Notes”); |
under the Company’s Registration Statement on Form S-3, Reg. No. 333-269836.
In connection with the offering of the Notes, the Company entered into an underwriting agreement on February 19, 2025, which is filed as Exhibit 1.1 hereto (the “Underwriting Agreement”), with Citigroup Global Markets Limited, Deutsche Bank AG, London Branch, Goldman Sachs & Co. LLC and the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell the Notes to the Underwriters. The Underwriting Agreement incorporates the Underwriting Agreement Standard Provisions (Debt), dated February 18. 2025, which is filed as Exhibit 1.2 hereto.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| JOHNSON & JOHNSON
(Registrant) | ||||||
| Date: February 26, 2025 | By: | /s/ Marc Larkins | ||||
| Marc Larkins | ||||||
| Corporate Secretary | ||||||